UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 5, 2016
| Endocyte, Inc. | ||
| (Exact name of registrant as specified in its charter) |
| Delaware | 001-35050 | 35-1969-140 | ||
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana |
47906 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 765-463-7175
| Not Applicable | ||
| Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure. |
The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
On January 5, 2016, Endocyte, Inc., a leader in developing targeted small molecule drug conjugates (SMDCs), announced that the United States District Court for the Southern District of Indiana dismissed the shareholder class action lawsuit filed in 2014 against Endocyte and certain of its officers, directors and underwriters in connection with the events leading up to cessation of the PROCEED Phase 3 clinical trial. In dismissing the lawsuit without prejudice, the Court stated that the plaintiffs must "demonstrate sufficient facts exist to justify an amended pleading” by February 1, 2016, or face a dismissal with prejudice.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Endocyte, Inc. | |||
| January 5, 2016 | By: | /s/ Beth A. Taylor | |
| Name: Beth A. Taylor | |||
| Title: Corporate Controller | |||